MARKET

DMPI

DMPI

DelMar Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7000
+0.0100
+1.45%
Opening 11:00 07/16 EDT
OPEN
0.7000
PREV CLOSE
0.6900
HIGH
0.7000
LOW
0.6915
VOLUME
51.32K
TURNOVER
--
52 WEEK HIGH
2.660
52 WEEK LOW
0.3800
MARKET CAP
8.02M
P/E (TTM)
-0.4965
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DMPI stock price target is 3.000 with a high estimate of 4.000 and a low estimate of 2.000.

EPS

DMPI News

More
DelMar Pharma receives loan for trial and study
Seeking Alpha - Article · 06/24 13:57
DelMar Pharma secures $500K loan to support advancement of VAL-083
Seeking Alpha - Article · 06/24 13:57
DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
PR Newswire · 06/24 13:30
DelMar Pharma Receives $500K Loan From National Brain Tumor Society, National Foundation For Cancer Research To Support VAL-083s Participation In Pivotal Study For Glioblastoma
Benzinga · 06/24 12:34
DelMar Pharma down 17% on underwhelming VAL-083 data
Seeking Alpha - Article · 06/22 16:35
DelMar Pharmaceuticals Presents Interim Data On VAL-083 Demonstrating Favorable Outcomes In Both Newly- Diagnosed And Recurrent GBM At AACR Annual Meeting II
SAN DIEGO, June 22, 2020 /PRNewswire/ --DelMar Pharmaceuticals, Inc.(NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor
Benzinga · 06/22 12:36
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment
PR Newswire · 06/22 12:30
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
Biotech stocks rebounded along with the broader market in the week ended June 19.
Benzinga · 06/21 18:53

Industry

Biotechnology & Medical Research
-1.32%
Pharmaceuticals & Medical Research
-1.01%

Hot Stocks

Symbol
Price
%Change

About DMPI

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a first-in-class, small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).
More

Webull offers kinds of DelMar Pharmaceuticals Inc stock information, including NASDAQ:DMPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DMPI stock methods without spending real money on the virtual paper trading platform.